April.2013-March.2014
-
03/02/2014Announcement of the commencement of patient enrollment in Phase II clinical study of cancer peptide vaccine S-588410 by Shionogi&Co., Ltd.
-
20/12/2013Announcement about the progress of phase III clinical trial (COMPETE-PC Study (COMbined PEptide ThErapy for Pancreatic Cancer)) of the peptide cocktail vaccine for patients with pancreatic cancer
-
09/12/2013Clinical Trial Application submitted for Phase I study of ONO-7268MX2,peptide-cocktail vaccine for hepatocellular carcinoma
-
02/12/2013Announcement of patent registrations
-
01/10/2013Announcement of the presentation of the final results for Phase II Clinical trial in patients with biliary tract cancer at the European Cancer Congress 2013.
-
01/10/2013Announcement of patent registrations
-
06/08/2013Announcement of the commencement of patient enrollment in Phase I clinical study of OTS167, a novel small molecule compound targeting cancer stem cells
-
05/08/2013Announcement of agreement on the collaborative research between OncoTherapy Science, Inc. and Fukushima Medical University
-
02/08/2013Announcement of the agreement on the collaborative development of the Electronic source data (“e-Source data”) system for clinical studies with ACRONET Corporation
-
01/08/2013Announcement of patent registrations from June to July in 2013
-
31/07/2013Announcement of trademark application of “Micelle-kun” for the compact automatic emulsion-preparing devices in Europe
-
30/07/2013Announcement of the license agreement granting SEPPIC the world-wide exclusive rights to manufacture and sell the compact automatic emulsion-preparing devices
-
29/07/2013Announcement about the progress of phase III clinical trial (COMPETE-PC Study(COMbined PEptide ThErapy for Pancreatic Cancer)) of the peptide cocktail vaccine for patients with pancreatic cancer
-
18/07/2013Announcement of new establishment of Immunological Monitoring Service Department
-
17/07/2013Announcement of agreement on collaborative development of automated-Specific Immuno-monitoring System for cancer immunotherapy
-
03/07/2013Announcement of clinical development pipelines
-
02/07/2013Announcement of FDA’s acceptance of Investigational New Drug (IND) application for Phase I clinical study of OTS167, a novel small molecule compound targeting cancer stem cells
-
03/06/2013Announcement of patents obtained in April and May 2013
-
27/05/2013Announcement of granting Nichirei Biosciences Inc. the rights to manufacture and sell the antibodies for use in pathological examination and research
-
24/05/2013Announcement of the acquisition of sole rights to obtain patents for results derived from the collaborative research with Kumamoto University
back to top